Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piero Fregatti

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Breast (Edinburgh, Scotland)|June 27, 2026
Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trialChiara Molinelli, Virginia Delucchi, Eva Blondeaux, et al.
European Journal of Cancer (Oxford, England : 1990)|February 6, 2026
Comparison of suboptimal versus adequate ovarian function suppression in premenopausal women with early breast cancer treated with adjuvant endocrine therapy: An exploratory analysis of two prospective studiesSimone Nardin, Marco Bruzzone, Luca Arecco, et al.
Eclinicalmedicine|May 31, 2023
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studiesMatteo Lambertini, Eva Blondeaux, Giancarlo Bisagni, et al.
International Journal of Surgery (London, England)|April 16, 2022
Reporting ChAracteristics of cadaver training and sUrgical studies: The CACTUS guidelinesGuglielmo Mantica, Rosario Leonardi, Raquel Diaz, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Breast (Edinburgh, Scotland)|June 27, 2026
Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trialChiara Molinelli, Virginia Delucchi, Eva Blondeaux, et al.
European Journal of Cancer (Oxford, England : 1990)|February 6, 2026
Comparison of suboptimal versus adequate ovarian function suppression in premenopausal women with early breast cancer treated with adjuvant endocrine therapy: An exploratory analysis of two prospective studiesSimone Nardin, Marco Bruzzone, Luca Arecco, et al.
Eclinicalmedicine|May 31, 2023
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studiesMatteo Lambertini, Eva Blondeaux, Giancarlo Bisagni, et al.
International Journal of Surgery (London, England)|April 16, 2022
Reporting ChAracteristics of cadaver training and sUrgical studies: The CACTUS guidelinesGuglielmo Mantica, Rosario Leonardi, Raquel Diaz, et al.
Pageof 7